UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 18,555,375 | $801,221,093 | -16% | 2.32% |
| 2. | Farallon Capital Thomas Steyer | 7,900,000 | $341,122,000 | +38% | 1.47% |
| 3. | Laurion Capital Management Benjamin A. Smith | 2,411,248 | $104,117,689 | -20% | 1.88% |
| 4. | D E Shaw D. E. Shaw | 2,081,253 | $89,868,504 | +2404% | 0.06% |
| 5. | 67,624,000 | $84,592,552 | -2% | 0.98% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $54.80 | 20,000 | $1,096,046.00 | 835,686 | 2025-10-09 | Filing | |
| $55.09 | 11,295 | $622,225.74 | 855,686 | 2025-10-08 | Filing | |
| $54.39 | 8,705 | $473,450.15 | 866,981 | 2025-10-08 | Filing | |
| $54.80 | 20,000 | $1,096,046.00 | 4,638,447 | 2025-10-09 | Filing | |
| $55.09 | 11,294 | $622,170.65 | 4,658,447 | 2025-10-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,180,000 | $33,991,035 | 0.03% | |
| 2. | 30,000,000 | $29,647,500 | 0.03% | |
| 3. | 473,496 | $24,593,382 | 0.02% | |
| 4. | 258,904 | $13,447,474 | 0.02% | |
| 5. | 205,900 | $10,694,446 | 0.47% |
News See All
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
12 Most Promising Long-Term Stocks to Buy
On September 12, Abby Joseph Cohen, Columbia Business School professor and former Goldman Sachs partner & chief US strategist, joined 'Squawk Box' on CNBC to discuss the latest market trends, state of...
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best Russell 2000 stocks to buy now. On August 6, TD Cowen reiterated its “Buy” rating on BridgeBio stock and maintained a price target of $60.
12 Best Russell 2000 Stocks to Buy Now
In its Weekly Market Monitor report for the week ending August 8, 2025, Goldman Sachs noted that U.S. equities had firmly recovered from their April lows.
Hedge Fund Resource Center Billionaire Hedge Funds
